SIRT6-IN-3

SIRT6-IN-3 (compound 8a) is a selective inhibitor of SIRT6 (IC50=7.49 μM) . SIRT6-IN-3 inhibits pancreatic ductal adenocarcinoma (PDAC) cells proliferation and induces apoptosis. SIRT6-IN-3 increases the sensitivity of cancer cells to gemcitabine (HY-17026) via blocking the DNA damage repair pathway. SIRT6-IN-3 is used in pancreatic cancer research[1].

Product Specifications

CAS Number

[3023471-40-8]

UNSPSC

12352005

Target

Akt; ERK; HDAC; mTOR; Ribosomal S6 Kinase (RSK) ; Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/sirt6-in-3.html

Purity

98.19

Solubility

DMSO : ≥ 120 mg/mL

Smiles

BrC1=C(Br)NC(C2=NC=CC3=C2N=CN3CCCCCCS/C(N(C)C)=[N+](C)\C)=C1.Cl.[Br-]

Molecular Formula

C21H30Br3ClN6S

Molecular Weight

673.73

References & Citations

[1]Song N, et al. Discovery of a pyrrole-pyridinimidazole derivative as novel SIRT6 inhibitor for sensitizing pancreatic cancer to gemcitabine. Cell Death Dis. 2023 Aug 4;14 (8) :499.